About this trial
The purpose of this research is to study whether adding an FDA approved medication called aprepitant (a medication given to patients like you to reduce or eliminate nausea and vomiting) to the usual treatment to prevent nausea and vomiting given to patients during knee replacement surgery helps more patients go home on the same day of surgery (before midnight) by eliminating nausea and vomiting.
Eligibility criteria
Qualifiers
Receiving primary, unilateral elective TKA with or without abductor canal block
Asa I-III
Age 18-90
Ability to receive ondansetron and dexamethasone
Disqualifiers
Allergy to any of the anti-emetics being administered
Current treatment of pimozide
Emergent surgery
Revision/ multiple revisions of TKA
Trial design
Treatments tested in this trial
- Aprepitant Injection
- Ondansetron (Zofran)
- Dexamethasone
- Placebo
Treatment groups
Sponsors and collaborators
Endeavor Health
Lead sponsor
Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.)
Collaborator